Fujifilm Diosynth breaks ground on a $1.6B expansion project in Denmark
As Fujifilm has been investing heavily in its CDMO arm for over a year, one of its major projects is now getting off the ground.
The Japanese manufacturer announced that it has broken ground on an expansion project at its site in the city of Hillerød, Denmark. The expansion, which was first announced in June, is part of a $1.6 billion project to expand the cell culture production capabilities in Denmark and at another facility in Texas.
While the expansion in Denmark has Fujifilm looking to create 450 jobs and boost the size of the facility, the company was mum on the size of the expansion. Endpoints News did reach out to Fujifilm Diosynth for further details and will update the story accordingly.
The company did reveal in a statement that the buildout will accommodate eight new 20,000-liter bioreactors and two downstream processing units. When the project is completed in 2026, the site will have 20 bioreactors for drug substance manufacturing. The addition of these bioreactors will also make the site one of the largest CDMO facilities in Europe.
The site will also feature environmentally friendly measures such as a net-zero carbon target, water conservation and renewable energy, among other green pushes.
As for Fujifilm’s expansion in Texas, no update on that project has been provided, but in July the company announced that the project will include an investment to expand cell culture manufacturing. Fujifilm plans to make use of its SymphonX and MaruX manufacturing platforms to allow for continuous processing.
The Denmark expansion is not the only move that Fujifilm is making where the price tag is jumping beyond 10 figures. Last year, the company settled on building a $2 billion plant in Holly Springs, NC to produce cell cultures.
Fujifilm also said last year that it was making an $850 million investment into gene therapy manufacturing at sites in the US and the UK, with those projects slated to be complete in 2023.